CM
Chris Mansi
Co-founder & CEO
Neurosurgeon who co-founded Viz.ai in 2016 at Stanford after seeing preventable patient deaths caused by slow care coordination during stroke emergencies.
Viz.ai is an AI-powered clinical care coordination platform deployed in over 1,700 hospitals across the US and Europe that uses machine learning to analyze medical imaging in real time and alert care teams to time-sensitive conditions like stroke, pulmonary embolism, and aortic dissection. The platform also supports pharma and life sciences companies in identifying eligible patients for clinical trials and therapies. Viz.ai was the first company to receive CMS reimbursement for an AI-based medical device.
Viz.ai is an AI-powered clinical care coordination platform deployed in over 1,700 hospitals across the US and Europe that uses machine learning to analyze medical imaging in real time and alert care teams to time-sensitive conditions like stroke, pulmonary embolism, and aortic dissection. The platform also supports pharma and life sciences companies in identifying eligible patients for clinical trials and therapies. Viz.ai was the first company to receive CMS reimbursement for an AI-based medical device.
Chris Mansi, a neurosurgeon, and David Golan, a machine learning postdoc, co-founded Viz.ai in 2016 after meeting at Stanford and recognizing that hospitals lacked data-driven tools to coordinate care for time-sensitive neurological emergencies. Mansi saw firsthand how treatment delays caused by communication breakdowns were leading to preventable deaths, and built Viz.ai to put AI directly into clinical workflows.
The suite unifies acute and chronic pulmonary workflows in a single platform. Viz PE was shown to cut time-to-treatment for high-risk patients from 1.75 days to 0.56 days.
Research at ACC.26 found Viz HCM AI-ECG identified 11 new HCM diagnoses and re-engaged patients lost to follow-up at The Christ Hospital Health Network.
Viz.ai's pharma and life sciences partnerships grew to 13 total in 2025, adding 6 new partnerships including Sanofi and Regeneron for COPD and Novartis for oncology.
Viz.ai was ranked the #1 Healthcare AI Platform by hospitals and health systems in the annual Black Book Research survey.
Viz.ai expanded its platform to over 1,700 hospitals across the US and Europe, covering 230 million+ lives with AI-powered care coordination.
Viz.ai reached unicorn status raising $100 million in Series D led by Tiger Global and Insight Partners as hospital deployments surpassed 1,000.
Viz.ai raised $71 million in Series C funding led by Kleiner Perkins with participation from GV and Salesforce Ventures to expand its AI care coordination platform.
Co-founder & CEO
Neurosurgeon who co-founded Viz.ai in 2016 at Stanford after seeing preventable patient deaths caused by slow care coordination during stroke emergencies.
Co-founder & CTO
Machine learning researcher who co-founded Viz.ai with Chris Mansi at Stanford; built the company's foundational AI/ML algorithms for medical image analysis.
$171M raised total
No H1B sponsorship data available for this company.